Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Public Advisory - Health Canada warns about multiple unauthorized health products that may pose serious health risks


OTTAWA, ON, Oct. 16, 2023 /CNW/ - Health Canada is advising that the following product(s) may pose serious health risks. For more information, including product photos and what you should do, visit the online safety alert:

Health Canada maintains lists of unauthorized health products that may pose serious health risks so that the public can easily identify those they may have purchased and take appropriate action. You are encouraged to check back regularly for updates.

Product

Hazard Identified

Company

Action Taken

Unauthorized health products for sexual enhancement

Black Panther #1

 

Labelled to contain yohimbe

Dépanneur Quévillon  

210 rue Quévillon,

Varennes QC

Seized from retail location  

Super Panther 7K

 

Labelled to contain yohimbe

Dépanneur Quévillon

210 rue Quévillon,

Varennes QC

Seized from retail location

Magnum Gold 24K

 

Product with similar
packaging (previously seized)
was tested and found to
contain tadalafil

Dépanneur Quévillon

210 rue Quévillon,

Varennes QC

Seized from retail location

Rhino 69 Platinum 35000  

 

Product with similar
packaging (previously seized)
was tested and found to
contain tadalafil

Dépanneur Quévillon

210 rue Quévillon,

Varennes QC

Seized from retail location

VIP Go Rhino 69K

Labelled to contain yohimbe    

Dépanneur Quévillon

210 rue Quévillon,

Varennes QC

Seized from retail location

Stay connected with Health Canada and receive the latest advisories and product recalls.

Également disponible en français

SOURCE Health Canada (HC)


These press releases may also interest you

at 06:18
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment...

at 01:13
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

1 jun 2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data of its novel drug candidate...

1 jun 2024
Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C inhibitor glecirasib (JAB-21822) in combination with a SHP2 inhibitor (JAB-3312) in frontline non-small cell lung...

1 jun 2024
EMA CHMP recommendation is based on the results of a Phase 3 clinical trial (GEMSTONE-302) demonstrating significant progression-free survival (PFS) and overall survival (OS) benefits of sugemalimab in combination with chemotherapy as a first-line...

1 jun 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: